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Alzheimer’s disease (AD) can be diagnosed according to new research criteria proposed recently (Dubois et al., 2007). Diagnosis is
made on grounds of episodic memory deﬁcits and one pathological biomarker: cerebrospinal ﬂuid (CSF) or structural/functional
imaging. Goal was to investigate the dependence of episodic memory function on material (verbal, visuospatial), gender and
premorbid intellectual ability (IQ). The new research criteria of AD were applied retrospectively using data of 68 patients
(Mini-Mental-Status Examination, MMSE ≥ 22) from a university memory clinic. Women with lower IQ performed worse on
visuospatial episodic memory than women with higher IQ and men with the same IQ. Thus, women with lower IQ appear to be
particularly vulnerable to visuospatial episodic memory deﬁcits despite similar CSF tau values indicating a similar activity of the
neurodegenerative process. Gender, premorbid IQ, and visuospatial material need to be considered in the assessment of episodic
memory breakdown applying the newly proposed research criteria for the diagnosis of AD.
Copyright © 2009 U. Beinhoﬀ et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Alzheimer’sdisease(AD)isoneofthemostcommondiseases
of old age [1–3]. Established research criteria for clinical
diagnosis of Alzheimer’s disease (AD) require diagnosis of
dementia syndrome and exclusion of possible causes of
dementia other than AD [4]. Recently, revised research
criteria for positive diagnosis of Alzheimer’s disease—with
or without clinical dementia syndrome—were proposed [5].
Other than the previous set of criteria diagnosis is not per-
formed by exclusion; the new set of criteria aim for a positive
diagnosis of AD. The revised criteria demand a signiﬁcant
episodic memory impairment which does not improve with
cuing plus an abnormal result for at least one biomarker:
mediotemporal atrophy on structural neuroimaging, an
AD-typical pattern on functional neuroimaging (PET or
SPECT), or AD-typical results for Abeta- and tau-protein
in cerebrospinal ﬂuid (CSF) analysis. With this framework,
diagnosis of AD does not require presence of dementia
syndrome.
The correlation between severity of dementia and neu-
ropathologyisloose[6–8].Onelikelycauseisthatthedisease
is driven by diﬀusible oligomeric amyloid assemblies causing
synaptic failure rather than by the amyloid depositions alone
[9, 10]. The clinical presentation of failure of synaptic trans-
mission inaﬀectedindividuals, however,varieswithpremor-
bidvariables[11].Epidemiologicevidencesuggeststhatindi-
v i d u a l sw i t hh i g h e rI Q[ 12], or higher educational or occu-
pationalattainment[13,14],orparticipationinleisureactiv-
ities [15] have an increased capacity for buﬀering the burden
of disease. Not only the capacity against decline may diﬀer
according to these variables but also the pattern of decline
[16] which in addition may be gender-dependent [17–19].
Investigations on healthy controls suggest a female
advantage in episodic memory with predominantly verbal
material and a male advantage for visuospatial tasks [20–30].
The impact of gender on memory in aging, however, further
is modiﬁed by general intellectual abilities [31].
It was the goal of the present study to analyze the
inﬂuence of both, gender and general intellectual abilities
on verbal and visuospatial episodic memory performance in
patients diagnosed with newly revised research criteria that
require at least one positive biomarker evidence for securing
AD diagnosis [5].2 International Journal of Alzheimer’s Disease
2. Methods
The study was done in accordance with the ethical standards
of the University Clinics (Berlin and Ulm). All persons gave
their informed consent prior to their inclusion in the study.
2.1. Study Sample. From the cohort of patients assessed
in a specialized dementia outpatient university hospital
service68patientswithmildcognitivedeﬁcits(Mini-Mental-
Status Examination, MMSE ≥ 22) were selected fulﬁlling
either the diagnosis of Alzheimer’s Disease according to
NINCDS-ADRDA criteria and DSM-IV or the criteria for
Mild Cognitive Impairment as deﬁned by Petersen [32].
Patients were only selected that contained necessary data
(IQ, neuropsychology, CSF (tau-protein, Abeta-protein), or
cerebral imaging) to apply the revised research criteria for
probable Alzheimer’s disease [5]. For ﬁnal analysis patients
were included when they had an episodic memory deﬁcit
that does not signiﬁcantly improve with cuing plus at least
one supportive ﬁnding (either abnormal CSF tau or Abeta
concentrations or medial temporal lobe (MTL) volume
loss assessed by a qualitative rating using MRI). Subjects
with other neurological or psychiatric diseases that could
explain memory deﬁcits were excluded, as well as subjects
who received medication that could interfere with cognitive
function. Basic characteristics of this sample are described in
Table 1.
2.2. Neuropsychological Tests
General Intellectual Abilities. It has been shown that intel-
ligence (i.e., reading ability) predicts incident dementia
better than education measured in number of years [33].
As a measure of crystallized (general) intelligence we used
a German vocabulary test (Wortschatztest, WST) [34].
Raw scores from the WST were converted into IQ scores,
according to the manual. Patients were grouped according
to general intellectual ability (low general intellectual ability
with IQ < 100 and high intellectual ability with IQ > 100).
Dementia Severity. Dementia severity was staged with the
MMSE [35]. In the present study, we included subjects with
aM M S Es c o r e≥ 22 because our goal was to describe gender
diﬀerences in the early stages of AD and patients with more
advanced stages of the disease are rarely able to complete
the comprehensive neuropsychological tests applied in this
study.
Episodic Memory. Verbal episodic memory with the imme-
diate and delayed recall of a word list was tested with
the German version of the California Verbal Learning Test
(CVLT) as previously applied [17, 36]. The word list is
a shopping list whose items can be grouped into four
categories (fruits, drinks, tools, clothes). This allows a cued
recall, where subjects have to recall all items belonging to
a speciﬁc category. As a measure of episodic memory (for
immediate and delayed recall), the percent rate of correctly
recalled words was used. Immediate and delayed recall of
geometric forms was tested with the visual reproduction test
(Wechsler Memory Scale, WMS) [37]. The percent rate of
correctly recalled shapes is reported. In accordance with the
Petersen criteria [32], the cut-oﬀ was set at 1.5SD.
2.3. Analysis of Cerebrospinal Fluid. Cerebrospinal ﬂuid
(CSF) routine parameters were analyzed. CSF for analysis of
tau-protein was frozen immediately after lumbar puncture
a n ds t o r e da t−80◦C. CSF tau concentrations were deter-
mined at the University of Ulm using a sandwich ELISA
(INNOTEST hTAU, Innogenetics) as described [38], which
recognizes normally phosphorylated and unphosphorylated
tau. The assay was adapted according to the protocol sup-
plied with the kit (laboratory reference ranges: <200pg/mL
and <300pg/mL for control individuals below 65 and older
than 65 years, resp.), and tau concentrations of the samples
were estimated from standard curves made for each assay.
Tau levels >200pg/mL (below 65 years) and >300pg/mL
(older than 65 years) were regarded as indicative of a neu-
rodegenerative process. The analytical sensitivity of the assay
was 75pg/mL, and the intraassay and interassay variation
was <8%. CSF Abeta-amyloid 1–42 levels were determined
using a sandwich ELISA developed several years ago [39]
and now commercially available (Innogenetics, Zwijndrecht,
Belgium).Theassaywasperformedaccordingtotheprotocol
supplied with the kit, and CSF Abeta concentrations of the
samples were estimated from standard curves made for each
assay. Abeta protein levels below 550pg/mL were regarded as
indicative of a neurodegenerative process.
2.4. Structural Neuroimaging. Structural cerebral imaging
with magnetic resonance imaging (MRI) was classiﬁed by
visual rating as representing normal ﬁndings or increased
medio-temporal atrophy. A detailed quantitative regional
analysis was beyond the scope of the present study.
2.5. Statistical Analysis. Four groups were compared in this
study: male and female AD patients with either high or low
intellectualability.Inordertoreducealpha-errorprobability,
statistical tests were applied in a hierarchical manner, that is,
diﬀerences between 2 single groups were only investigated
if the overall analysis of all four groups revealed signiﬁcant
diﬀerences. In order to provide comparability to other
studies, data are presented as mean values with standard
deviation (SD) and ranges. All statistical analyses were
carried out using nonparametric testing (chi-square, Mann-
Whitney-U-Test, Kruskal-Wallis test) applying the statistics
program SPSS (SPSS 15.0 for Windows, Chicago, Ill, USA).
3. Results
The four groups were equal according to number of patients
(N, Chi-square, P>. 05) and age (Kruskal-Wallis-Test,
P>. 05) but diﬀered in their MMSE scores (Kruskal-Wallis
test, P = .03). Men in the high IQ group had higher MMSE
scores than men in the low IQ group (U-Test, P = .028) and
women in the high IQ group (U-Test, P = .044).International Journal of Alzheimer’s Disease 3
Table 1: Characterization of the study sample: ranges, mean, and standard deviations in brackets. MMSE: Mini-Mental Status Examination;
WST: German Vocabulary Test (Wortschatztest) as a measure of Intelligence; CSF: cerebrospinal ﬂuid; Low IQ (IQ < 100); High IQ (IQ >
100).
Low IQ (N = 35) High IQ (N = 33)
Male Female Male Female
N 20 15 18 15
Age 57–80 58–85 56–81 58–85
(68.0 ± 7.0) (71.1 ± 8.0) (70.0 ± 8.6) (68.7 ± 8.6)
MMSE 22–30 22–29 24–30 22–30
(26.3 ± 2.3) (25.7 ± 2.2) (27.8 ± 1.7)∗ (26.1 ± 2.4)
WST 17–30 12–30 31–39 31–39
(23.8 ± 4.0) (24.5 ± 4.9) (34.4 ± 2.5) (33.7 ± 2.1)
CSF tau 100–1658 74–1242 75–1428 200–1500
(463 ± 387) (494 ± 298) (431 ± 366) (770 ± 413)§
CSF Abeta 109–1140 262–1380 100–1351 221–1153
(624 ± 310) (523 ± 287) (700 ± 377) (533 ± 275)
Number of Abnormal biomarkers#
One: N = 10 One: N = 4 One: N = 10 One: N = 4
Two: N = 8T w o : N = 11 Two: N = 6T w o : N = 10
Three: N = 2 Three: N = 0 Three: N = 2 Three: N = 1
∗: signiﬁcant diﬀerence to high IQ females and low IQ males; §: signiﬁcant diﬀerence to high IQ males; #: CSF tau, CSF Abeta, MRI.
The number of abnormal biomarkers (CSF tau, CSF
Abeta, MRI) was not signiﬁcantly diﬀerent between the
four groups (Kruskal-Wallis test, P>. 05). CSF biomarkers
revealed similar levels for CSF Abeta-protein in all four
groups (Kruskal-Wallis test, P>. 05) but diﬀerences in
CSF tau levels (Kruskal-Wallis test, P = .039). Women in
the high IQ group had higher CSF tau values than men in
the high IQ group (U-Test, P = .012). Although women
with higher IQ had numerically increased values for CSF
tau than women with lower IQ, this diﬀerence reached no
signiﬁcance.CSFtauvaluesweresimilarforwomenandmen
in low IQ patients.
The results of the episodic memory function for verbal
and visuospatial material are presented in Table 2.O v e r a l l
analysisrevealedsimilarresultsforallfourgroupsinepisodic
memory function for verbal material (Kruskal-Wallis test,
P>. 05).
However,episodicmemorysigniﬁcantlydiﬀeredbetween
the four groups for visuospatial material (Kruskal-Wallice
test, immediate recall: P = .018; delayed recall: P = .001).
In delayed recall male AD patients achieved better test results
than female patients (low IQ group: U-Test, P = .009; high
IQ group: U-Test, P = .036). High IQ male patients showed
better results than low IQ male patients in immediate recall
(U-Test, P = .03). In delayed recall, women with higher
IQ performed better than women with lower IQ (U-Test,
P = .026).
4. Discussion
Recently, research criteria for the diagnosis of Alzheimer’s
disease (AD) have been proposed [5]. With this framework,
diagnosis of AD is achieved on ﬁnding an episodic memory
deﬁcit plus AD-typical biological markers (e.g., CSF tau
protein and Abeta-protein, atrophy on structural imaging).
Considering the gender-speciﬁc proﬁle of memory in AD
patients[17]andmodulationofmemoryinhealthyadultsby
generalintellectualabilities[40,41],itwasthegoaltoexplore
both, the inﬂuence of intelligence and gender on verbal and
visuospatial memory in AD patients.
It has been proposed that CSF t-tau concentrations
reﬂect the intensity or activity of the neurodegenerative
process[42,43].ThisissupportedbytherespectiveCSFt-tau
concentrations in various diseases with diﬀerent progression
rates (CJD > AD > ALS > MS). In addition, within a
single disease entity, the CSF t-tau concentration likely
indicates a faster progression rate [44–46]. In AD, the tau
levels in CSF correlate with the annual atrophy rate [47].
Abeta on the other hand has been proposed to give a
measure of how far the disease process already has proceeded
[42]. This is supported by the ﬁndings that the degree of
atrophy measured on structural cerebral imaging [47]o r
Abeta deposition evaluated in vivo with positron emission
tomography [48] correlate with CSF Abeta levels.
4.1. The Role of IQ. High functioning elders are particularly
diﬃcult to diagnose, as they score too high on standard
tests for which the norms were established in populations
of average general intellectual abilities [49]. Comparable
to other studies in healthy adults [12, 40, 41], we found
signiﬁcant diﬀerences in cognitive function in AD patients
depending on their premorbid IQ level. Male AD patients
with higher IQ had better test results regarding their
immediate memory for visuospatial material than male AD4 International Journal of Alzheimer’s Disease
Table 2: Values for episodic memory function (in % of maximum score): means (SD).
Immediate recall Verbal Visuospatial
Low IQ High IQ Low IQ High IQ
Male 44.7 (18.1) 55.6 (14.4) 52.2 (18.8)$ 65.0 (15.3)
Female 40.4 (21.9) 52.9 (24.6) 46.0 (15.5) 55.6 (17.1)
Long delayed recall Verbal Visuospatial
Low IQ High IQ Low IQ High IQ
Male 24.4 (18.9) 36.8 (21.7) 34.6 (30.4) 48.8 (27.5)
Female 19.2 (27.3) 30.8 (27.4) 10.3 (14.8)∗ 27.9 (26.2)§
∗: signiﬁcant diﬀerence to high IQ females and low IQ males; §: signiﬁcant diﬀerence to high IQ males; $: signiﬁcant diﬀerence to high IQ males.
Low  IQ High IQ
Female Male Female Male
CSF tau level in comparison to visuospatial
episodic memory (long delay)
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Figure 1: Visuospatial episodic memory performance (bars indi-
cate % of maximum score) in comparison to CSF tau values (lines)
in male and female AD patients. Higher memory scores indicate
better performance. Higher CSF tau values indicate more advanced
disease (activity).
patients with lower IQ. CSF tau values (i.e., disease activity)
were not diﬀerent for male AD patients. These ﬁndings
indicate a higher capacity for men with higher intelligence.
Similar resultswerefoundin femalepatients forlong delayed
recall of visuospatial material. Although their CSF tau value
was numerically (but not signiﬁcantly) increased, women
with higher IQ showed even better test results on their
visuospatial episodic memory than women with lower IQ
(see Figure 1), also indicating a higher capacity for women
with higher intelligence.
4.2. The Role of Gender. In the present study, we found
gender-diﬀerences in episodic memory function for visu-
ospatial material depending on IQ level. In the lower IQ
group, men performed better than women. CSF tau (i.e.,
disease activity) values were similar in both groups. This
result indicates that despite same levels of disease activity,
male AD patients are better in remembering visuospatial
material despite same levels of disease activity compared to
female AD patients. In the higher IQ group, women also
performed worse than men. CSF tau values for the high
IQ group were increased for women, showing that disease
activity was higher in this group. In a further analysis
controlling for disease activity (CSF tau-value), gender
diﬀerences in episodic memory function disappear, that is,
no advantage for males was observed. We speculate that
women with higher intellectual abilities might use strategies
(e.g., verbalization of the material) which may explain the
absenceofgenderdiﬀerencesforvisuospatialmaterialatleast
in the high IQ group. For future studies, material which is
less subject to verbalization than even the present geometric
patterns should be used.
Gender diﬀerences in the verbal domain that are well
established for healthy controls [31] were not observed in the
present study on patients with mild AD. Most likely, aging
[28] and the disease process obscures gender speciﬁcities
observed in healthy adult individuals.
5. Conclusion
Our results show that both IQ and gender modulate episodic
memoryinADpatientsinamodality speciﬁcfashion(verbal
versus visuospatial). Women with lower IQ appear to be par-
ticularly vulnerable to visuospatial episodic memory deﬁcits.
The dependence on gender and general intellectual capacity
in episodic memory breakdown needs to be considered in
thenewlyproposedresearchcriteriaforthediagnosisofearly
Alzheimer’s disease.
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